Increasingly, scientific advances are delivering new medicines that deliver improved survival and quality of life across multiple treatment indications. Indication-Based Pricing (IBP) has been proposed as a way to better link price with value. In this short Discussion Paper, we outline the major issues including the potential benefits of IBP, potential drawbacks, and considerations for implementation. We then ask for your views. To submit your thoughts, please access the survey which accompanies the Discussion Paper. Consultation closing date: Monday, 30 September 2019.
Although the science is in the middle of the process, we have made a difference. Increasingly, medicines will have multiple indications. New payment mechanisms are being proposed with the innovation landscape. One such mechanism is allowing the healthcare system to support different indications for a different indication of a medicine: indication-based pricing (IBP).
OHE previously launched a Discussion Paper (now also available in Spanish), which outlines the key potential benefits and drawbacks of IBP, along with considerations for implementation. This is accompanied by a consultation exercise , where we ask you to contribute your thoughts.
The consultation closes on Monday, 30 September 2019.
See below to access the survey in French.
…………………………………………………………………………………………………………………………………………………………………….
Fixation du prix selon l’indication thérapeutique (FPIT). Le prix des médicaments devrait-il différer selon l’indication thérapeutique?
De plus en plus, la science à l’origine du développement des médicaments permettra améliorer la survie et qualité de vie dans plusieurs indications thérapeutiques. Aussi, il convient de rechercher de nouveaux mécanismes de rémunération répondant à cette situation. Un mécanisme permet au système de santé de fixer, pour un médicament, différents prix pour différentes indications thérapeutiques : c’est la fixation du prix selon l’indication thérapeutique (FPIT) qui permet lier le prix avec la valeur d’un médicament selon les différentes indications. Nous souhaiterions échanger et recueillir différents points de vue sur les avantages et inconvénients potentiels pour réfléchir sur la mise en œuvre du FPIT. Nous souhaiterions connaître votre propre point de vue.
Pour partager vos réflexions, accédez aux questions pour y répondre en cliquant sur le lien qui vous dirigera directement vers
l’enquête en ligne.
Date de fin de la consultation : lundi, 30 septembre 2019.
…………………………………………………………………………………………………………………………………………………………………….
Citation
Cole, A., Towse, A. and Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper . OHE Briefing, London: Office of Health Economics.
Related research
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M., 2015. Multi-indication pricing: pros, cons and applicability to the UK . OHE Seminar Briefing, Office of Health Economics.
Cole, A., Towse, A., Lorgelly, P. and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals . Research Paper, Office of Health Economics.
Towse, A., Cole, A. and Zamora, B., 2018. The Debate on Indication-Based Pricing in the US and Five Major European Countries . Consulting Report, Office of Health Economics.
Neri, M., Towse, A., and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward . OHE Briefing, Office of Health Economics.
